GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » Owner Earnings per Share (TTM)

Anika Therapeutics (Anika Therapeutics) Owner Earnings per Share (TTM) : -6.16 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Anika Therapeutics's Owner Earnings per Share (TTM) ended in Dec. 2023 was $-6.16. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Anika Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Anika Therapeutics was 83.59. The lowest was 13.95. And the median was 27.90.


ANIK's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.985
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Anika Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-4.30. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.65. It's PE Ratio ratio for today is At Loss.

Anika Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.73. It's PE Ratio without NRI ratio for today is At Loss.


Anika Therapeutics Owner Earnings per Share (TTM) Historical Data

The historical data trend for Anika Therapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Owner Earnings per Share (TTM) Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.41 -2.33 -0.13 -1.42 -6.16

Anika Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.42 -1.62 -2.44 -2.16 -6.16

Competitive Comparison of Anika Therapeutics's Owner Earnings per Share (TTM)

For the Medical Instruments & Supplies subindustry, Anika Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Price-to-Owner-Earnings falls into.



Anika Therapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Anika Therapeutics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -82.7
Depreciation, Depletion and Amortization 14.2
Change In Deferred Tax -6.3
5Y Average of Maintenance Capital Expenditure 3.4
Change In Working Capital -12.1
Shares Outstanding (Diluted Average) 14.6

1. Start with "Net Income" from income statement. Anika Therapeutics's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-82.7 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Anika Therapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was $14.2 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Anika Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.3 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $3.4 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Anika Therapeutics's 5-Year Average Maintenance Capital Expenditure = $3.4 Mil

5. "Change In Working Capital" is from cashflow statement. Anika Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.1 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Anika Therapeutics's Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 14.647 Mil.

Anika Therapeutics's Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -82.667 +14.217+-6.327
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-3.3660718991417+-12.123)/14.647
=-6.16

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=26.06/-6.16
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Anika Therapeutics Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics (Anika Therapeutics) Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767